Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image
Decoration of PLGA-PEG polymeric nanoparticles with cancer specific peptide ligand for active dual targeting delivery system
3rd International Conference on Nanotek & Expo
December 02-04, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Madhu Gupta

Accepted Abstracts: J Nanomed Nanotechnol

Abstract:

Certain tumor cells overexpress a membrane-spanning molecule, aminopeptidase N (CD13) isoform, which is the receptor for peptides containing the NGR motif. NGR-modified docetaxel (DTX)-loaded PEG-b-PLGA polymeric nanoparticles (NGR-NP-DTX) were developed and evaluated for their in vitro potential in HT-1080 cell line. The NGR-NP-DTX containing particles were about 148 nm in diameter with spherical shape and high encapsulation efficiency. Cellular uptake was confirmed both qualitatively and quantitatively by confocal laser scanning microscopy (CLSM) and flow cytometry. Both quantitatively and qualitatively results confirmed the NGR conjugated nanoparticles revealed the higher uptake of nanoparticles by CD13- overexpressed tumor cells. Free NGR inhibited the cellular uptake of NGR-NP-DTX, revealing the mechanism of receptor mediated endocytosis. In vitro cytotoxicity studies demonstrated that NGR-NP-DTX formulation was more cytotoxic than unconjugated one, which were consistent well with the observation of cellular uptake. Hence, the selective delivery of NGR- NP-DTX formulation in CD13-overexpressing tumors represents a potential approach for the design of nanocarrier-based dual targeted delivery systems for targeting the tumor cells and vasculature

Biography :

Madhu Gupta is a Research Associate in the Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar, India. She has about 07 years of research experience. She is pioneer scientist in the field of nanotechnology and drug delivery field. She has judiously exploited bioligands for targeting of bioactives and drug moiety. She has over 20 research publications to her credit published in journals of high scientific impact and contributed 04 chapters in various renowned books and to several international and national books. She is a National Doctoral fellowship awardee at Department of Pharmaceutical Sciences (India). She is a recipient of best poster award in the nanomedicine field for 2 nd International Science Congress held in Mathura (India). She is an active member of APTI in India. She is an acclaimed academician and researcher of high repute. She serves on the potential reviewer of various high repute journals. She is widely visited scientist and delivered invited/popular/keynote addresses in national conferences in India